A population-based retrospective cohort study of data from more than 40,000 UK patients has determined that knee or hip replacements are more likely to last longer in patients who take bisphosphonates than those who do not (implant survival hazard ratio 0.54 [95% CI 0.29–0.99]; P = 0.047). Patients who used bisphosphonates had a lower rate of prosthetic revision 5 years after primary placement of the prosthesis than nonusers.